Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
August 28 2017 - 04:05PM
Business Wire
Deep international expertise to drive the
Company’s global expansion
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic medicines company specializing in therapeutics based on
its proprietary hyaluronic acid ("HA") technology, today announced
the appointment of Steven Chartier as Vice President of Regulatory
and Clinical Affairs. Mr. Chartier brings more than 25 years of
operational expertise leading global regulatory strategy,
especially in the Asia Pacific markets, and clinical development
for emerging and established companies in the medical technology
and biotechnology industries. In his new role at Anika, Mr.
Chartier will be responsible for overseeing and directing the
clinical development course for the Company’s orthobiologics and
regenerative medicine pipeline and advancing promising candidates
like CINGAL® and HYALOFAST® through U.S. and ex-U.S. regulatory
channels.
“We’re excited to strengthen and solidify our regulatory and
clinical development capabilities with the addition of Mr.
Chartier, a veteran regulatory and clinical affairs professional
with proven expertise in spearheading regulatory strategy and
leading a wide array of products through U.S. and global
approvals,” said Charles H. Sherwood, Ph.D., Chief Executive
Officer of Anika Therapeutics. “Mr. Chartier is the latest of the
strategic, senior-level hires we’ve made to advance our robust
orthobiologics and regenerative medicine pipeline, and build out
our direct commercialization capabilities that will bring forth the
next decade of growth for Anika.”
Most recently, Mr. Chartier served as Vice President of
Regulatory Affairs and Quality Assurance at Augmenix, Inc., a
growth-oriented, privately-held medical device company focused on
improving the outcomes of radiotherapy through the use of
absorbable hydrogels. Prior to his time at Augmenix, Mr. Chartier
served as Chief Operations Officer at PixarBio Corporation and
Chief Operating Officer at Infraredx, Inc., where he developed
broad operational prowess and led U.S. and global regulatory,
quality and clinical development strategy for these entrepreneurial
organizations. Mr. Chartier also held positions at Biogen, Inc., a
large public company opportunity where he honed his clinical
development skills, and at Nucryst Pharmaceuticals, where he spent
almost a decade building and maintaining the regulatory and quality
functions to support worldwide approval and compliance of regulated
medical device and pharmaceutical products.
“Anika’s expansive commercial portfolio and global footprint are
impressive, and I see tremendous potential in its diversified
product pipeline that lends itself to a steady flow of regulatory
filings and approvals in the U.S. and overseas,” said Steven
Chartier, Vice President of Regulatory and Clinical Affairs at
Anika Therapeutics. “I believe my experience working with Asia
Pacific regulatory authorities will be especially valuable to
Anika, as this region represents a tremendous growth opportunity
for the orthopedic medicine market.”
Mr. Chartier launched his career in clinical research and
clinical trial coordination at Dana Farber Cancer Institute and
Beth Israel Deaconess Medical Center. Mr. Chartier received a
Regulatory Affairs Certification from the Regulatory Affairs
Professional Society in 2003, and he holds a Bachelor of Arts in
Psychology from Saint Anselm College. Click HERE to view
Mr. Chartier’s full bio.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated orthopedic medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative cartilage
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®, and CINGAL, which
alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage
repair and regeneration. For more information about Anika, please
visit www.anikatherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170828005961/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerorFor Media Inquiries:Pure
CommunicationsSonal Vasudev, 917-523-1418,
sonal@purecommunicationsinc.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2023 to Mar 2024